TAYSHA GENE THERAPIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.39 USD | +3.91% |
|
+5.29% | +35.03% |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Taysha Gene...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.39
USD
Average target price
6.833
USD
Spread / Average Target
+185.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.03% | 447M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Transcript : Taysha Gene Therapies, Inc., Q3 2023 Earnings Call, Nov 14, 2023
